Enhanced Measurement of Genetic Sequence Complexity to Drive Clinical Insights
Statistics-first. No reference genome required. Unbiased discovery.
Benefits of Rosa Bio Technology
- ROSA's "statistics first" Semore platform allows detection of genomic complexity missed by other methods
- Allows faster, cheaper, smarter genomics analysis
- Readily scalable
- Agnostic to nucleic acid type: DNA (WGS and targeted), RNA, short and long read, exome, non-coding regions, ctDNA, bisulfite, etc.
- Detects structure-based changes, not based on gene panels
- Can be used with tissue sample or liquid biopsy (plasma cfDNA)
- Semore software output = AI-ready
- Diverse applications: Dx, Tx, other
Panoptic. Faster. Cheaper.
Speed
Faster processing, lower overhead.
Accuracy
Assess all sequence variation in a sample with no bias.
Cost
High-efficiency analysis tools.
A Statistics-First Approach.
A new paradigm for analysis of nucleic acid sequence information. Unlike traditional methods, we require no reference genome for sequence alignment.
Our approach enables truly unbiased discovery, identifying patterns and variations that conventional tools simply cannot detect.
Why Statistics First
Our statistics-first approach analyzes raw data directly, eliminating reference genome bias and enabling detection of all genomic complexity.
White Paper
Read our white paper on the benefits of a statistics-first approach to genomic analysis.
Precision Medicine Applications
Patient stratification using sequence variation that predicts treatment response and disease progression.
Leadership.
Julia Salzman
Founder & CSO
Associate Professor in the Department of Biomedical Data Science, and by courtesy in Biology and Statistics at Stanford University. A.B. in Mathematics from Princeton University magna cum laude and Ph.D. from Stanford University in Statistics. Developed statistical algorithms that discovered circular RNA and the SPLASH suite of statistics-first genomic algorithms. Research funded by NIH, NSF, CZI. Recognized with Alfred P. Sloan Fellowship, McCormick-Gabilan Fellowship, and NSF CAREER Award.
Michael Rabson
Co-Founder & CEO
More than 25 years of experience in life sciences. Former partner at Wilson Sonsini Goodrich & Rosati for 15 years. Served as General Counsel of Maxygen (MAXY) and Cytokinetics (CYTK). Former patent examiner at USPTO focused on biotechnology. Member of the patent bar. Author of scientific publications in Science, Nature, PNAS. Ph.D. from Yale University and J.D. from Yale Law School.